Top Ten most popular articles on Pharmafile.com this week
As Friday comes round again, this week saw some of the biggest news of the year: Amsterdam is the new home of the EMA after the agency’s HQ was forced to move from its London home as a result of Brexit. The decision was shockingly decided by random lottery after becoming locked in a tie with Milan.
Elsewhere, the first-ever European biosimilar approval of Roche’s immunotherapy Herceptin has been passed, setting off a spark in the region that is sure to lead to close competition as others race to bring their own versions to market.
And just in time for the holidays, Teva has announced a massive staff cut, and it’s rumoured that up to 25% of all Israel-based staff could face the axe – a staggering 6,860 employees.
Check out the week’s ten most popular articles on Pharmafile.com now!
Boehringer Ingelheim has unveiled opnME.com, a centralised platform which makes available selected pre-clinical molecules from its portfolio for free, accessible for non-clinical investigation by scientists worldwide.
Acorda Therapeutics has announced that it is terminate development of its Parkinson’s therapy tozadenant after five deaths were reported as a result of trialling the drug.
Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq in combination with Avastin and chemotherapy in the treatment of lung cancer.
In good news for coffee drinkers, drinking three to four cups of coffee was found to lower the risk of certain cancers, diabetes-risk, liver disease and dementia. Researchers concluded that coffee is “more likely to benefit health than to harm it”, after collating a number of studies together.
In a decision that was likened to a penalty shoot-out, Amsterdam was announced as the winner of the race to become the new home of the EMA headquarters on a coin-toss decision.
Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be achieved if clinicians, academics, industry leaders and policymakers work together.
In a 10-year study conducted at the Indiana University School of Medicine, researchers were able to observe a 29% reduced risk of developing dementia in patients who participated in a certain kind of computer-based training.
GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of HIV.
Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe by the EMA for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.
With the appointment of Kåre Schultz, the company hopes that it can take some hard decisions to turn around the company – one of the first steps seems to be to fire a large number of staff.
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …